Valproate-induced liver injury

Modulation by the omega-3 fatty acid DHA proposes a novel anticonvulsant regimen

Marwa A. Abdel-Dayem, Ahmed Abdelrazik Elmarakby, Azza A. Abdel-Aziz, Chelsey Pye, Shehta A. Said, Abdalla M. El-Mowafy

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: The polyunsaturated, ω-3 fatty acid, docosahexaenoic acid (DHA), claims diverse cytoprotective potentials, although via largely undefined triggers. Thus, we currently first tested the ability of DHA to ameliorate valproate (VPA)-evoked hepatotoxicity, to modulate its anticonvulsant effects, then sought the cellular and molecular basis of such actions. Lastly, we also verified whether DHA may kinetically alter plasma levels/clearance rate of VPA. Methods and Results: VPA (500 mg/kg orally for 14 days in rats) evoked prominent hepatotoxicity that appeared as a marked rise (2- to 4-fold) in serum hepatic enzymes (γ-glutamyl transferase [γ-GT], alanine aminotransferase [ALT], and alkaline phosphatase [ALP]), increased hepatic lipid peroxide (LPO) and tumor necrosis factor-alpha (TNFα) levels, as well as myeloperoxidase (MPO) activity (3- to 5-fold), lowering of serum albumin (40 %), and depletion of liver reduced-glutathione (GSH, 35 %). Likewise, histopathologic examination revealed hepatocellular degeneration, replacement by inflammatory cells, focal pericentral necrosis, and micro/macrovesicular steatosis. Concurrent treatment with DHA (250 mg/kg) markedly blunted the elevated levels of liver enzymes, lipid peroxides, TNFα, and MPO activity, while raising serum albumin and hepatic GSH levels. DHA also alleviated most of the cytologic insults linked to VPA. Besides, in a pentylenetetrazole (PTZ) mouse convulsion model, DHA (250 mg/kg) markedly increased the latency in convulsion evoked by VPA, beyond their individual responses. Lastly, pharmacokinetic studies revealed that joint DHA administration did not alter serum VPA concentrations. Conclusions: DHA substantially ameliorated liver injury induced by VPA, while also markedly boosted its pharmacologic effects. DHA manipulated definite cellular machinery to curb liver oxidative stress and inflammation, without affecting VPA plasma levels. Collectively, these protective and synergy profiles for DHA propose a superior VPA-drug combination regimen.

Original languageEnglish (US)
Pages (from-to)85-94
Number of pages10
JournalDrugs in R and D
Volume14
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Docosahexaenoic Acids
Omega-3 Fatty Acids
Valproic Acid
Anticonvulsants
Liver
Wounds and Injuries
Lipid Peroxides
Serum Albumin
Peroxidase
Seizures
Tumor Necrosis Factor-alpha
Pentylenetetrazole
Drug Combinations
Enzymes
Transferases
Serum
Alanine Transaminase
Unsaturated Fatty Acids
Glutathione
Alkaline Phosphatase

ASJC Scopus subject areas

  • Pharmacology

Cite this

Valproate-induced liver injury : Modulation by the omega-3 fatty acid DHA proposes a novel anticonvulsant regimen. / Abdel-Dayem, Marwa A.; Elmarakby, Ahmed Abdelrazik; Abdel-Aziz, Azza A.; Pye, Chelsey; Said, Shehta A.; El-Mowafy, Abdalla M.

In: Drugs in R and D, Vol. 14, No. 2, 01.01.2014, p. 85-94.

Research output: Contribution to journalArticle

Abdel-Dayem, Marwa A. ; Elmarakby, Ahmed Abdelrazik ; Abdel-Aziz, Azza A. ; Pye, Chelsey ; Said, Shehta A. ; El-Mowafy, Abdalla M. / Valproate-induced liver injury : Modulation by the omega-3 fatty acid DHA proposes a novel anticonvulsant regimen. In: Drugs in R and D. 2014 ; Vol. 14, No. 2. pp. 85-94.
@article{545f9ea643734339bbe4e1b373677f81,
title = "Valproate-induced liver injury: Modulation by the omega-3 fatty acid DHA proposes a novel anticonvulsant regimen",
abstract = "Background: The polyunsaturated, ω-3 fatty acid, docosahexaenoic acid (DHA), claims diverse cytoprotective potentials, although via largely undefined triggers. Thus, we currently first tested the ability of DHA to ameliorate valproate (VPA)-evoked hepatotoxicity, to modulate its anticonvulsant effects, then sought the cellular and molecular basis of such actions. Lastly, we also verified whether DHA may kinetically alter plasma levels/clearance rate of VPA. Methods and Results: VPA (500 mg/kg orally for 14 days in rats) evoked prominent hepatotoxicity that appeared as a marked rise (2- to 4-fold) in serum hepatic enzymes (γ-glutamyl transferase [γ-GT], alanine aminotransferase [ALT], and alkaline phosphatase [ALP]), increased hepatic lipid peroxide (LPO) and tumor necrosis factor-alpha (TNFα) levels, as well as myeloperoxidase (MPO) activity (3- to 5-fold), lowering of serum albumin (40 {\%}), and depletion of liver reduced-glutathione (GSH, 35 {\%}). Likewise, histopathologic examination revealed hepatocellular degeneration, replacement by inflammatory cells, focal pericentral necrosis, and micro/macrovesicular steatosis. Concurrent treatment with DHA (250 mg/kg) markedly blunted the elevated levels of liver enzymes, lipid peroxides, TNFα, and MPO activity, while raising serum albumin and hepatic GSH levels. DHA also alleviated most of the cytologic insults linked to VPA. Besides, in a pentylenetetrazole (PTZ) mouse convulsion model, DHA (250 mg/kg) markedly increased the latency in convulsion evoked by VPA, beyond their individual responses. Lastly, pharmacokinetic studies revealed that joint DHA administration did not alter serum VPA concentrations. Conclusions: DHA substantially ameliorated liver injury induced by VPA, while also markedly boosted its pharmacologic effects. DHA manipulated definite cellular machinery to curb liver oxidative stress and inflammation, without affecting VPA plasma levels. Collectively, these protective and synergy profiles for DHA propose a superior VPA-drug combination regimen.",
author = "Abdel-Dayem, {Marwa A.} and Elmarakby, {Ahmed Abdelrazik} and Abdel-Aziz, {Azza A.} and Chelsey Pye and Said, {Shehta A.} and El-Mowafy, {Abdalla M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s40268-014-0042-z",
language = "English (US)",
volume = "14",
pages = "85--94",
journal = "Drugs in R and D",
issn = "1174-5886",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Valproate-induced liver injury

T2 - Modulation by the omega-3 fatty acid DHA proposes a novel anticonvulsant regimen

AU - Abdel-Dayem, Marwa A.

AU - Elmarakby, Ahmed Abdelrazik

AU - Abdel-Aziz, Azza A.

AU - Pye, Chelsey

AU - Said, Shehta A.

AU - El-Mowafy, Abdalla M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: The polyunsaturated, ω-3 fatty acid, docosahexaenoic acid (DHA), claims diverse cytoprotective potentials, although via largely undefined triggers. Thus, we currently first tested the ability of DHA to ameliorate valproate (VPA)-evoked hepatotoxicity, to modulate its anticonvulsant effects, then sought the cellular and molecular basis of such actions. Lastly, we also verified whether DHA may kinetically alter plasma levels/clearance rate of VPA. Methods and Results: VPA (500 mg/kg orally for 14 days in rats) evoked prominent hepatotoxicity that appeared as a marked rise (2- to 4-fold) in serum hepatic enzymes (γ-glutamyl transferase [γ-GT], alanine aminotransferase [ALT], and alkaline phosphatase [ALP]), increased hepatic lipid peroxide (LPO) and tumor necrosis factor-alpha (TNFα) levels, as well as myeloperoxidase (MPO) activity (3- to 5-fold), lowering of serum albumin (40 %), and depletion of liver reduced-glutathione (GSH, 35 %). Likewise, histopathologic examination revealed hepatocellular degeneration, replacement by inflammatory cells, focal pericentral necrosis, and micro/macrovesicular steatosis. Concurrent treatment with DHA (250 mg/kg) markedly blunted the elevated levels of liver enzymes, lipid peroxides, TNFα, and MPO activity, while raising serum albumin and hepatic GSH levels. DHA also alleviated most of the cytologic insults linked to VPA. Besides, in a pentylenetetrazole (PTZ) mouse convulsion model, DHA (250 mg/kg) markedly increased the latency in convulsion evoked by VPA, beyond their individual responses. Lastly, pharmacokinetic studies revealed that joint DHA administration did not alter serum VPA concentrations. Conclusions: DHA substantially ameliorated liver injury induced by VPA, while also markedly boosted its pharmacologic effects. DHA manipulated definite cellular machinery to curb liver oxidative stress and inflammation, without affecting VPA plasma levels. Collectively, these protective and synergy profiles for DHA propose a superior VPA-drug combination regimen.

AB - Background: The polyunsaturated, ω-3 fatty acid, docosahexaenoic acid (DHA), claims diverse cytoprotective potentials, although via largely undefined triggers. Thus, we currently first tested the ability of DHA to ameliorate valproate (VPA)-evoked hepatotoxicity, to modulate its anticonvulsant effects, then sought the cellular and molecular basis of such actions. Lastly, we also verified whether DHA may kinetically alter plasma levels/clearance rate of VPA. Methods and Results: VPA (500 mg/kg orally for 14 days in rats) evoked prominent hepatotoxicity that appeared as a marked rise (2- to 4-fold) in serum hepatic enzymes (γ-glutamyl transferase [γ-GT], alanine aminotransferase [ALT], and alkaline phosphatase [ALP]), increased hepatic lipid peroxide (LPO) and tumor necrosis factor-alpha (TNFα) levels, as well as myeloperoxidase (MPO) activity (3- to 5-fold), lowering of serum albumin (40 %), and depletion of liver reduced-glutathione (GSH, 35 %). Likewise, histopathologic examination revealed hepatocellular degeneration, replacement by inflammatory cells, focal pericentral necrosis, and micro/macrovesicular steatosis. Concurrent treatment with DHA (250 mg/kg) markedly blunted the elevated levels of liver enzymes, lipid peroxides, TNFα, and MPO activity, while raising serum albumin and hepatic GSH levels. DHA also alleviated most of the cytologic insults linked to VPA. Besides, in a pentylenetetrazole (PTZ) mouse convulsion model, DHA (250 mg/kg) markedly increased the latency in convulsion evoked by VPA, beyond their individual responses. Lastly, pharmacokinetic studies revealed that joint DHA administration did not alter serum VPA concentrations. Conclusions: DHA substantially ameliorated liver injury induced by VPA, while also markedly boosted its pharmacologic effects. DHA manipulated definite cellular machinery to curb liver oxidative stress and inflammation, without affecting VPA plasma levels. Collectively, these protective and synergy profiles for DHA propose a superior VPA-drug combination regimen.

UR - http://www.scopus.com/inward/record.url?scp=84904322731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904322731&partnerID=8YFLogxK

U2 - 10.1007/s40268-014-0042-z

DO - 10.1007/s40268-014-0042-z

M3 - Article

VL - 14

SP - 85

EP - 94

JO - Drugs in R and D

JF - Drugs in R and D

SN - 1174-5886

IS - 2

ER -